Epidemiology and Control of Mansonella Perstans Infection in Uganda
Information source: DBL -Institute for Health Research and Development
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Mansonelliasis; Pruritus; Lymphoedema; Abdominal Pains
Intervention: ivermectin and albendazole (Drug)
Phase: N/A
Status: Completed
Sponsored by: DBL -Institute for Health Research and Development Official(s) and/or principal investigator(s): Asanta M Asio, Msc, Principal Investigator, Affiliation: Vector control Division, Kampala, Uganda
Summary
Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the
epidemiology of this infection, and of the morbidity it induces is poor, and no effective
treatment is available. The study aims at providing data on diagnostic, epidemiological,
morbidity and treatment aspects of M. perstans infections in Uganda.
Clinical Details
Official title: Studies on the Epidemiology and Control of Mansonella Perstans Infection in Uganda
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: microfilariae periodicity patternsepidemiology of M. perstans at community level clinical spectre among infected reduction in microfilaraemia
Secondary outcome: treatment effect on clinical manifestations
Detailed description:
Overall objective: to investigate diagnostic, epidemiological and treatment aspects of M.
perstans in Uganda with relevance to control
Specific objectives:
1. To establish the pattern of diurnal periodicity of M. perstans microfilaraemia in
humans
2. To establish the patterns of M. perstans microfilaraemia and possible clinical
manifestations related to this infection in two communities with medium to high
endemicity
3. To determine the efficacy of ivermectin alone and the combination of ivermectin and
albendazole on M. perstans microfilaraemia.
Eligibility
Minimum age: 5 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Individuals >= 5 years with or without M. perstans infection
Exclusion Criteria:
- Individuals < 5 years
- Pregnant women
Locations and Contacts
Luwero, Luwero and Mukono, Luwero and Mukono Districts, Uganda
Additional Information
Starting date: November 2005
Last updated: April 19, 2007
|